FDA Clears Removal of Suicide Warning From Labels for GLP-1 Weight-Loss Drugs

Regulators said a review found no evidence of a link between the drugs and suicidal thoughts.

Boxes for the medications Wegovy and Zepbound, in a file photograph in California on May 8, 2025. JoNel Aleccia/AP Photo

Labels for popular weight-loss drugs no longer need to warn that they may increase the risk of suicide, federal regulators said in a Jan. 13 update.

The Food and Drug Administration said that it informed companies that manufacture Glucagon-Like Peptide-1 (GLP-1) agonists that labels for the drugs no longer need to mention suicidal behavior and ideation.